Across TCGA pan-cancer cohorts, ANKRD13B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD13B data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANKRD13B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD13B expression acts as an unfavorable survival marker.

LIHC, UCEC, and COAD are the cancer types where ANKRD13B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.028	0.775	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	II,III,IV	0.220	0.779	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANKRD13B tumor-vs-normal RNA expression · all ANKRD13B data types